The European Medicines Agency (EMA)’s Committee for Medicinal Products (CHMP) has adopted a positive opinion recommending marketing authorisation for a chronic spontaneous urticaria (CSU) treatment.  The opinion means remibrutinib, a highly selective oral BTKi developed by Novartis, could be the first targeted therapy approved for CSU in Europe.  The positive CHMP opinion is supported by results from the REMIX-1 […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!